Physician profile
Maliha Ahmad
NPI 1902067952
$554,245.46
in general payments reported to CMS, 2019-2025
18 companies · $208K in 2025
The $208K reported for 2025 was more than what 98% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $62K · 2021: $42K · 2022: $38K · 2023: $51K · 2024: $94K · 2025: $208K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $251K · Travel and Lodging: $35K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $29K · Consulting Fee: $22K · Food and Beverage: $14K · Honoraria: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $251,302.63 |
| Travel and Lodging | $34,792.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,640.00 |
| Consulting Fee | $22,010.00 |
| Food and Beverage | $13,778.85 |
| Honoraria | $2,285.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $235,621.09 | 2019-2025 | Livdelzi, Vemlidy, Epclusa |
| Madrigal Pharmaceuticals | $97,923.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65,830.25 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $49,966.32 | 2019-2025 | Mavyret |
| Ipsen Biopharmaceuticals, INC | $43,560.44 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $31,830.92 | 2019-2025 | Ocaliva |
| Novo Nordisk INC | $28,359.35 | 2024-2025 | Wegovy |
| Intra-Sana Laboratories | $223.72 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sirtex Medical INC | $217.10 | 2019-2022 | |
| Echosens North America, INC. | $200.50 | 2019 | |
| Argenx US, INC. | $193.90 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mallinckrodt Hospital Products INC. | $78.59 | 2022-2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $57.30 | 2019-2020 | |
| Dynavax Technologies Corporation | $43.41 | 2021-2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $39.90 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $36.90 | 2024-2025 | Cuvrior |
| Janssen Biotech, INC. | $35.61 | 2025 | |
| Eisai INC. | $27.01 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maliha Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.